We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Huntington Ingalls' (HII) Division Wins $108M Navy Deal
Read MoreHide Full Article
Huntington Ingalls Industries Inc.'s (HII - Free Report) unit, Ingalls Shipbuilding, recently secured a $108-million modification contract for providing integrated yard support services to the Littoral combat in-service ships (LCS). The contract was awarded by the Naval Sea Systems Command, Washington, DC.
Details of the Deal
Per the contract terms, the Ingalls Shipbuilding division will offer ship installation drawings development support, ship change document updates, operating cycle integration program management and work integration package engineering support services.
It will further provide research engineering and modeling, integrated planning yard material support, mechanical and electrical engineering standardization support, alongside other services. Majority of the deal-related work will be performed in Hampton, VA, and Pascagoula, MS. The entire task is expected to be completed by April 2021.
A Brief Note on LCS
Currently, there are two different variants of the Littoral Combat Ship, which are being used and operated by the U.S. Navy, known as Freedom and Independence. Both variants are designed for operating in near-shore environments but also equipped to perform open-ocean operations. It is designed to defeat asymmetric anti-access threats, such as mines, quiet diesel submarines and fast surface craft.
What’s Favoring Huntington Ingalls?
The fiscal 2020 defense budget approved by the U.S. Senate in mid-2019 provisioned a spending plan of $34.7 billion for shipbuilding, reflecting an 88.6% surge from the fiscal 2019 budget. Huntington Ingalls specializes in manufacturing amphibious assault and expeditionary ships along with its associated services. Therefore, such budgetary developments should enable the company to procure more significant contracts related to providing yard support services, like the latest one.
Looking ahead, per Technavio, the global naval shipbuilding market is expected to reach $14.36 billion in 2024, at a CAGR of 3% from 2020. This, in turn, should potentially increase the demand for various combat ships, including the LCS and its required services. Notably, Huntington Ingalls is likely to benefit from such favorable projections, going forward.
Price Movement
In a year’s time, shares of Huntington Ingalls have lost 10.6% compared with the industry’s 24.2% decline.
Other top-ranked stocks in the same sector include Leidos Holdings, Inc. (LDOS - Free Report) , AeroVironment, Inc. (AVAV - Free Report) and Moog Inc. (MOG.A - Free Report) . While AeroVironment sports a Zacks Rank #1, Leidos and Moog carries a Zacks Rank #2, at present.
Leidos Holdings delivered a four-quarter earnings beat of 11.2%, on average. The Zacks Consensus Estimate for 2020 earnings has risen 0.7% to $5.49 over the past 90 days.
AeroVironment came up with a positive earnings surprise of 5.7%, on average, in the last four quarters. The Zacks Consensus Estimate for 2020 earnings has risen 8.6% to $1.77 over the past 90 days.
Moog pulled off a positive earnings surprise of 4.8%, on average, in the trailing four quarters. The Zacks Consensus Estimate for 2019 earnings has moved 0.9% north to $5.55 over the past 90 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Huntington Ingalls' (HII) Division Wins $108M Navy Deal
Huntington Ingalls Industries Inc.'s (HII - Free Report) unit, Ingalls Shipbuilding, recently secured a $108-million modification contract for providing integrated yard support services to the Littoral combat in-service ships (LCS). The contract was awarded by the Naval Sea Systems Command, Washington, DC.
Details of the Deal
Per the contract terms, the Ingalls Shipbuilding division will offer ship installation drawings development support, ship change document updates, operating cycle integration program management and work integration package engineering support services.
It will further provide research engineering and modeling, integrated planning yard material support, mechanical and electrical engineering standardization support, alongside other services. Majority of the deal-related work will be performed in Hampton, VA, and Pascagoula, MS. The entire task is expected to be completed by April 2021.
A Brief Note on LCS
Currently, there are two different variants of the Littoral Combat Ship, which are being used and operated by the U.S. Navy, known as Freedom and Independence. Both variants are designed for operating in near-shore environments but also equipped to perform open-ocean operations. It is designed to defeat asymmetric anti-access threats, such as mines, quiet diesel submarines and fast surface craft.
What’s Favoring Huntington Ingalls?
The fiscal 2020 defense budget approved by the U.S. Senate in mid-2019 provisioned a spending plan of $34.7 billion for shipbuilding, reflecting an 88.6% surge from the fiscal 2019 budget. Huntington Ingalls specializes in manufacturing amphibious assault and expeditionary ships along with its associated services. Therefore, such budgetary developments should enable the company to procure more significant contracts related to providing yard support services, like the latest one.
Looking ahead, per Technavio, the global naval shipbuilding market is expected to reach $14.36 billion in 2024, at a CAGR of 3% from 2020. This, in turn, should potentially increase the demand for various combat ships, including the LCS and its required services. Notably, Huntington Ingalls is likely to benefit from such favorable projections, going forward.
Price Movement
In a year’s time, shares of Huntington Ingalls have lost 10.6% compared with the industry’s 24.2% decline.
Zacks Rank & Other Key Picks
Huntington Ingalls currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other top-ranked stocks in the same sector include Leidos Holdings, Inc. (LDOS - Free Report) , AeroVironment, Inc. (AVAV - Free Report) and Moog Inc. (MOG.A - Free Report) . While AeroVironment sports a Zacks Rank #1, Leidos and Moog carries a Zacks Rank #2, at present.
Leidos Holdings delivered a four-quarter earnings beat of 11.2%, on average. The Zacks Consensus Estimate for 2020 earnings has risen 0.7% to $5.49 over the past 90 days.
AeroVironment came up with a positive earnings surprise of 5.7%, on average, in the last four quarters. The Zacks Consensus Estimate for 2020 earnings has risen 8.6% to $1.77 over the past 90 days.
Moog pulled off a positive earnings surprise of 4.8%, on average, in the trailing four quarters. The Zacks Consensus Estimate for 2019 earnings has moved 0.9% north to $5.55 over the past 90 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>